Abbott reports success in mid-stage psoriasis trial

Abbott Laboratories announced positive data from a mid-stage study of its experimental psoriasis drug ABT-874, a follow-up drug to Humira. Aside from the control group, researchers divided up patients into five groups which received different doses. At least 90 percent of the patients in four of the five groups saw a 75 percent improvement in the severity of their skin lesions.

- check out the release on the drug

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.